Fig. 3.

In vivo target inhibition by LY2835219. a tumors harvested 24 h after dosing for analysis with the markers topoIIα (S phase-specific), p-Rb (pRb ser 780, G1-specific), pHH3 (M-specific), and the Rb/E2F regulated proteins DHFR, RRM1 and RRM2. GAPDH was used as a loading control. statistical significance (p <0.05) is indicated above each dose by an asterisk for pRb, Topollα, and pHH3, respectively. b time course of LY2835219. tumor-bearing animals were dosed orally with 50 mg/kg of LY2835219 and tumors harvested at the indicated times (n = 5 per treatment, n = 8 for vehicle). the percent change in band intensity was calculated using vehicle-treated bands as 100 %. mean (±SD) plasma concentrations of the compound are shown in the lower right panel